Suppr超能文献

相似文献

1
Akt and mTORC1 have different roles during liver tumorigenesis in mice.
Gastroenterology. 2013 May;144(5):1055-65. doi: 10.1053/j.gastro.2013.01.053. Epub 2013 Jan 30.
3
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
Gastroenterology. 2011 Mar;140(3):1071-83. doi: 10.1053/j.gastro.2010.12.006. Epub 2010 Dec 11.
5
Livers with constitutive mTORC1 activity resist steatosis independent of feedback suppression of Akt.
PLoS One. 2015 Feb 3;10(2):e0117000. doi: 10.1371/journal.pone.0117000. eCollection 2015.
8
mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Gastroenterology. 2015 Sep;149(3):741-52.e14. doi: 10.1053/j.gastro.2015.05.005. Epub 2015 May 14.

引用本文的文献

1
Genetic evidence for the causal influence of inflammatory factors on intrahepatic cholangiocarcinoma risk.
World J Gastrointest Oncol. 2025 Jul 15;17(7):108455. doi: 10.4251/wjgo.v17.i7.108455.
2
Albumin promoter-driven FlpO expression induces efficient genetic recombination in mouse liver.
Am J Physiol Gastrointest Liver Physiol. 2024 May 1;326(5):G495-G503. doi: 10.1152/ajpgi.00263.2023. Epub 2024 Mar 12.
3
PTEN deficiency potentiates HBV-associated liver cancer development through augmented GP73/GOLM1.
J Transl Med. 2024 Mar 8;22(1):254. doi: 10.1186/s12967-024-04976-4.
4
An overview of mouse models of hepatocellular carcinoma.
Infect Agent Cancer. 2023 Sep 5;18(1):49. doi: 10.1186/s13027-023-00524-9.
5
Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma.
Pharmaceutics. 2023 Aug 14;15(8):2130. doi: 10.3390/pharmaceutics15082130.
6
Convergent genomic diversity and novel BCAA metabolism in intrahepatic cholangiocarcinoma.
Br J Cancer. 2023 Jun;128(12):2206-2217. doi: 10.1038/s41416-023-02256-4. Epub 2023 Apr 19.
10
Role of mechanistic target of rapamycin in autophagy and alcohol-associated liver disease.
Am J Physiol Cell Physiol. 2022 Oct 1;323(4):C1100-C1111. doi: 10.1152/ajpcell.00281.2022. Epub 2022 Sep 5.

本文引用的文献

1
Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.
Sci Signal. 2012 Mar 27;5(217):ra24. doi: 10.1126/scisignal.2002739.
2
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
Clin Cancer Res. 2012 Apr 1;18(7):2090-8. doi: 10.1158/1078-0432.CCR-11-1991. Epub 2012 Jan 11.
3
The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis.
Hum Pathol. 2012 May;43(5):737-46. doi: 10.1016/j.humpath.2011.07.005. Epub 2011 Oct 20.
5
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.
Cancer. 2011 Nov 15;117(22):5094-102. doi: 10.1002/cncr.26165. Epub 2011 Apr 27.
6
High-resolution characterization of a hepatocellular carcinoma genome.
Nat Genet. 2011 May;43(5):464-9. doi: 10.1038/ng.804. Epub 2011 Apr 17.
7
Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation.
PLoS One. 2011 Mar 29;6(3):e18075. doi: 10.1371/journal.pone.0018075.
8
mTOR: from growth signal integration to cancer, diabetes and ageing.
Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35. doi: 10.1038/nrm3025. Epub 2010 Dec 15.
9
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
Gastroenterology. 2011 Mar;140(3):1071-83. doi: 10.1053/j.gastro.2010.12.006. Epub 2010 Dec 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验